drugset
drugset / Trial / NCT04506567

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT04506567 ↗

Phase 1/2 Active not recruiting 60 enrolled Weill Medical College of Cornell University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591, that can be given without severe side effects. The purpose of the second (phase II) portion of the study is to determine the proportion of those with PSMA-positive tumors with \>50% PSA decline following 225Ac-J591 treatment in two regimens.

Timeline

Start
2020-08-18
Primary completion
2025-06-01
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 225Ac-J591 Monoclonal antibody — —

Indications

prostate cancer